<bill session="105" type="hc" number="113" updated="2013-07-14T18:51:16-04:00">
  <state datetime="1997-07-09">REFERRED</state>
  <status>
    <introduced datetime="1997-07-09"/>
  </status>
  <introduced datetime="1997-07-09"/>
  <titles>
    <title as="introduced" type="official">Expressing the sense of Congress about the Food and Drug Administration proposal to designate the use of chlorofluorocarbons in metered-dose inhalers as non-essential.</title>
  </titles>
  <sponsor id="400388"/>
  <cosponsors>
    <cosponsor id="400169" joined="1997-07-09"/>
    <cosponsor id="400380" joined="1997-07-09"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="1997-07-09">
      <text>Referred to the House Committee on Commerce.</text>
    </action>
    <action datetime="1997-07-14">
      <text>Referred to the Subcommittee on Health and Environment.</text>
      <committee name="House Committee on Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF04" subcommittee="Health and Environment" name="House Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative procedure"/>
    <term name="Air pollution control"/>
    <term name="Asthma"/>
    <term name="Chlorofluorocarbons"/>
    <term name="Commerce"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Environmental protection"/>
    <term name="Government operations and politics"/>
    <term name="International affairs"/>
    <term name="International environmental cooperation"/>
    <term name="Law"/>
    <term name="Medical supplies"/>
    <term name="Ozone layer depletion"/>
    <term name="Treaties"/>
  </subjects>
  <amendments/>
  <summary>7/9/1997--Introduced.
Expresses the sense of the Congress that: (1) a specified proposed Food and Drug Administration (FDA) regulation to designate the use of chlorofluorocarbons (CFCs) in metered-dose inhalers (MDIs) as nonessential so as to make MDIs using CFCs adulterated devices puts at risk the health of millions of asthma patients and does not contribute measurably to protection of the environment; and (2) the FDA should withdraw its proposal and focus its efforts on implementing existing Montreal Protocol decisions that will facilitate a transition to CFC-free MDIs by 2005.</summary>
</bill>
